1.      Ahn JH, Kim AR, Lee C, et al. Type 1 Sialidosis Patient With a Novel Deletion Mutation in the NEU1 Gene: Case Report and Literature Review. Cerebellum. 2019;18(3):659-664. doi:10.1007/S12311-019-1005-2

2.      Al-Saady M, Beerepoot S, Plug BC, et al. Neurodegenerative disease after hematopoietic stem cell transplantation in metachromatic leukodystrophy. Ann Clin Transl Neurol. 2023;10(7):1146-1159. doi:10.1002/ACN3.51796

3.      Al-Saif A. Approach to neurodegenerative disease in children: a short review. Pediatrics & Neonatal Biology Open Access. 2018;1(1):000121. doi:10.32474/PAPN.2018.01.000121

4.      Aldosari M, Altuwaijri M, Husain AM. Brain-stem auditory and visual evoked potentials in children with Krabbe disease. Clinical Neurophysiology. 2004;115(7):1653-1656. doi:10.1016/j.clinph.2004.02.022

5.      Arora V, Setia N, Dalal A, et al. Sialidosis type II: Expansion of phenotypic spectrum and identification of a common mutation in seven patients. Mol Genet Metab Rep. 2020;22. doi:10.1016/J.YMGMR.2019.100561

6.      Bingaman A, Waggoner C, Andrews SM, et al. GM1‐gangliosidosis: The caregivers’ assessments of symptom impact and most important symptoms to treat. Am J Med Genet A. 2022;191(2):408. doi:10.1002/AJMG.A.63038

7.      Biswas A, Malhotra M, Mankad K, et al. Clinico-radiological phenotyping and diagnostic pathways in childhood neurometabolic disorders—a practical introductory guide. Transl Pediatr. 2021;10(4):1201-30. doi:10.21037/tp-20-335.

8.      Black DN, Taber KH, Hurley RA. Metachromatic leukodystrophy: a model for the study of psychosis. J Neuropsychiatry Clin Neurosci. 2003;15(3):289-293. doi:10.1176/JNP.15.3.289

9.      Bley A, Denecke J, Kohlschütter A, et al. The natural history of Canavan disease: 23 new cases and comparison with patients from literature. Orphanet J Rare Dis. 2021;16(1):1-9. doi:10.1186/S13023-020-01659-3/FIGURES/3

10.  Blondel A, Kraoua I, Marcelino C, et al. Plasma GM2 ganglioside potential biomarker for diagnosis, prognosis and disease monitoring of GM2-Gangliosidosis. Mol Genet Metab. 2023;138(2). doi:10.1016/J.YMGME.2022.106983

11.  Bricker K, Vaughn B V. Rett syndrome: a review of clinical manifestations and therapeutic approaches. Frontiers in Sleep. 2024;3. doi:10.3389/FRSLE.2024.1373489/FULL

12.  Eichler F, Grodd W, Grant E, et al. Metachromatic leukodystrophy: a scoring system for brain MR imaging observations. AJNR Am J Neuroradiol. 2009;30(10):1893-1897. doi:10.3174/ajnr.A1739.

13.  Escolar ML, Poe MD, Martin HR, Kurtzberg J. A staging system for infantile Krabbe disease to predict outcome after unrelated umbilical cord blood transplantation. Pediatrics. 2006;118(3). doi:10.1542/PEDS.2006-0747

14.  Farina L, Bizzi A, Finocchiaro G, et al. MR imaging and proton MR spectroscopy in adult Krabbe disease. AJNR Am J Neuroradiol. 2000;21(8):1478-1482.

15.  Gedik KC, Lamot L, Romano M, et al. The 2021 EULAR and ACR points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS. Ann Rheum Dis. 2022;81(5):601. doi:10.1136/annrheumdıs-2021-221814

16.  Gold WA, Percy AK, Neul JL, et al. Rett syndrome. Nature Reviews Disease Primers 2024 10:1. 2024;10(1):1-17. doi:10.1038/s41572-024-00568-0

17.  Gowda VK, Bhat MD, Srinivasan VM, Prasad C, Benakappa A, Faruq M. A case of Canavan disease with microcephaly. Brain Dev. 2016;38(8):759-762. doi:10.1016/j.braindev.2016.03.001

18.  Hayflick SJ, Kurian MA, Hogarth P. Neurodegeneration with brain iron accumulation. Handb Clin Neurol. 2018;147:293. doi:10.1016/B978-0-444-63233-3.00019-1

19.  Hoshino H, Kubota M. Canavan disease: clinical features and recent advances in research. Pediatr Int. 2014;56(4):477-483. doi:10.1111/PED.12422

20.  Jafar B, Sharma K, Sheikh A, Maertens P. The novel use of a synthetic amino acid analog in the management of Menkes’ disease. J Pediatr Neurol. 2022;20(6):415-418. doi:10.1055/s-0042-1742687.

21.  Koike M, Shibata M, Waguri S, et al. Participation of Autophagy in Storage of Lysosomes in Neurons from Mouse Models of Neuronal Ceroid-Lipofuscinoses (Batten Disease). Am J Pathol. 2005;167(6):1713-1728. doi:10.1016/S0002-9440(10)61253-9

22.  Komatsuzaki S, Zielonka M, Mountford WK, et al. Clinical characteristics of 248 patients with Krabbe disease: quantitative natural history modeling based on published cases. Genetics in Medicine. 2019;21(10):2208-2215. doi:10.1038/S41436-019-0480-7.

23.  Laur D, Pichard S, Bekri S, et al. Natural history of GM1 gangliosidosis-Retrospective cohort study of 61 French patients from 1998 to 2019. J Inherit Metab Dis. 2023;46(5):972-981. doi:10.1002/JIMD.12646

24.  Leal AF, Cifuentes J, Quezada V, et al. CRISPR/nCas9-Based Genome Editing on GM2 Gangliosidoses Fibroblasts via Non-Viral Vectors. Int J Mol Sci. 2022;23(18). doi:10.3390/IJMS231810672

25.  Lefter S, Ryan AM. Late-Onset Tay-Sachs Disease - expanding the clinical phenotype. Tremor Other Hyperkinet Mov (N Y). 2023;13(1). doi:10.5334/TOHM.750

26.  Livingston JH, Crow YJ. Neurologic Phenotypes Associated with Mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1, and IFIH1: Aicardi-Goutières Syndrome and Beyond. Neuropediatrics. 2016;47(6):355-360. doi:10.1055/S-0036-1592307

27.  Martakis K, Claassen J, Gascon-Bayari J, et al. Efficacy and Safety of N-Acetyl-l-Leucine in Children and Adults With GM2 Gangliosidoses. Neurology. 2023;100(10):E1072-E1083. doi:10.1212/WNL.0000000000201660

28.  Menkes disease: MedlinePlus Medical Encyclopedia. Accessed October 9, 2025. https://medlineplus.gov/ency/article/001160.htm?utm_source=chatgpt.com

29.  Mitsutake A, Matsukawa T, Iwata A, et al. Favorable outcome of hematopoietic stem cell transplantation in late-onset Krabbe disease. Brain Dev. 2023;45(7):408-412. doi:10.1016/J.BRAINDEV.2023.04.001

30.  Mole SE, Williams RE, Goebel HH, eds. The Neuronal Ceroid Lipofuscinoses (Batten Disease). Oxford University Press; 2011. doi:10.1093/med/9780199590018.001.0001.

31.  Piccoli C, Bronner N, Gavazzi F, et al. Late-Onset Aicardi-Goutières Syndrome: A Characterization of Presenting Clinical Features. Pediatr Neurol. 2021;115:1-6. doi:10.1016/j.pedıatrneurol.2020.10.012

32.  Platt FM, d’Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases. Nat Rev Dis Primers. 2018;4(1):27. doi:10.1038/s41572-018-0025-4

33.  Prust M, Wang J, Morizono H, et al. GFAP mutations, age at onset, and clinical subtypes in Alexander disease. Neurology. 2011;77(13):1287-1294. doi:10.1212/WNL.0B013E3182309F72

34.  Sandhoff K, Harzer K. Gangliosides and gangliosidoses: principles of molecular and metabolic pathogenesis. J Neurosci. 2013;33(25):10195-10208. doi:10.1523/JNEUROSCI.0822-13.2013.

35.  Sheppard H, Tasker R. Tell Your Story. London, UK: Crown House Publishing; 2017.

36.  Simonati A, Williams RE. Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview. Front Neurol. 2022;13:811686. doi:10.3389/FNEUR.2022.811686/FULL

37.  Swaiman KF, Ashwal S, Ferriero DM, Schor NF, Finkel RS, Gropman AL, Pearl PL, Shevell M, eds. Swaiman’s Pediatric Neurology: Principles and Practice. 7th ed. Philadelphia, PA: Elsevier; 2025.

38.  Utz JRJ, Crutcher T, Schneider J, Sorgen P, Whitley CB. Biomarkers of central nervous system inflammation in infantile and juvenile gangliosidoses. Mol Genet Metab. 2015;114(2):274-280. doi:10.1016/J.YMGME.2014.11.015

39.  Vairo FP e., Chwal BC, Perini S, Ferreira MAP, de Freitas Lopes AC, Saute JAM. A systematic review and evidence-based guideline for diagnosis and treatment of Menkes disease. Mol Genet Metab. 2019;126(1):6-13. doi:10.1016/J.YMGME.2018.12.005

40.  Yin JH, Hu WZ, Huang Y. Clinical and genetic features of a case with juvenile-onset Sandhoff disease. BMC Neurol. 2023;23(1):275. doi:10.1186/s12883-023-03267-7.